| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | OSCR | Class A Common Stock | Purchase | $3.75M | +276K | +5.8% | $13.58 | 5.03M | Nov 11, 2024 | See footnote | F1, F2 |
| transaction | OSCR | Class A Common Stock | Purchase | $5.76M | +421K | +8.36% | $13.68 | 5.45M | Nov 12, 2024 | See footnote | F2, F3 |
| transaction | OSCR | Class A Common Stock | Purchase | $4.93M | +359K | +6.58% | $13.74 | 5.81M | Nov 13, 2024 | See footnote | F2, F4 |
| Id | Content |
|---|---|
| F1 | Represents (i) 272,754 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,286 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.205 to $13.92, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,971,366 shares are held directly by Thrive VII Growth and 59,896 shares are held directly by Claremount VII. |
| F2 | Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. |
| F3 | Represents (i) 415,808 shares purchased by Thrive VII Growth and (ii) 5,011 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.45 to $14.29, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,387,174 shares are held directly by Thrive VII Growth and 64,907 shares are held directly by Claremount VII. |
| F4 | Represents (i) 354,349 shares purchased by Thrive VII Growth and (ii) 4,270 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.435 to $14.21, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,741,523 shares are held directly by Thrive VII Growth and 69,177shares are held directly by Claremount VII. |
Joshua Kushner has been deputized to represent the Reporting Persons on the board of directors of the Issuer. By virtue of Mr. Kushner's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the Reporting Persons may be deemed directors by deputization of the Issuer. Mr. Kushner has filed a separate Section 16 report disclosing securities of the Issuer that he may be deemed to beneficially own for Section 16 purposes.